Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Liabilities and Shareholders Equity (2023 - 2026)

Beta Bionics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $304.4 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 9.94% to $304.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.3 billion, a 165.18% increase, with the full-year FY2025 number at $328.7 million, up 119.68% from a year prior.
  • Liabilities and Shareholders Equity hit $304.4 million in Q1 2026 for Beta Bionics, down from $328.7 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BBNX hit a ceiling of $338.0 million in Q1 2025 and a floor of $110.0 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $270.1 million across 4 years, with a median of $328.7 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 119.68% in 2025 and later fell 9.94% in 2026.
  • Tracing BBNX's Liabilities and Shareholders Equity over 4 years: stood at $110.0 million in 2023, then skyrocketed by 35.99% to $149.6 million in 2024, then soared by 119.68% to $328.7 million in 2025, then fell by 7.4% to $304.4 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for BBNX at $304.4 million in Q1 2026, $328.7 million in Q4 2025, and $330.0 million in Q3 2025.